Ranolazine: Ion-channel-blocking actions and in vivo electrophysiological effects

British Journal of Pharmacology

Volumn 142, Issue 8, 2004, Pages 1300-1308

  Schram, Gernot ^a,b   Zhang, Liming ^a   Derakhchan, Katayoun ^a,c   Ehrlich, Joachim R ^a   Belardinelli, Luiz ^d   Nattel, Stanley ^a,c,d  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d CV THERAPEUTICS INC   (United States)

Author keywords

Acquired LQTS; Arrhythmogenesis; Dog model; Ionic basis; Patch clamp; Ranolazine; Two electrode voltage clamp

Indexed keywords

ION CHANNEL; POTASSIUM CHANNEL HERG; RANOLAZINE; SOTALOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG POTENCY; ELECTRODE; EXPERIMENTAL MODEL; FEMALE; HEART ATRIUM MUSCLE; HEART ELECTROPHYSIOLOGY; HEART RHYTHM; HEART VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; IC 50; LONG QT SYNDROME; MUSCLE CELL; NONHUMAN; OOCYTE; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; REFRACTORY PERIOD; TORSADE DES POINTES; VOLTAGE CLAMP; XENOPUS LAEVIS;

ANIMALS; CATION TRANSPORT PROTEINS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; ION CHANNELS; PIPERAZINES; POTASSIUM CHANNELS, VOLTAGE-GATED; XENOPUS;

EID: 4444302203     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705879     Document Type: Article

References (46)

1. ABBOTT, G.W., SESTI, F., SPLAWSKI, I., BUCK, M.E., LEHMANN, M.H., TIMOTHY, K.W., KEATING, M.T. & GOLDSTEIN, S.A. (1999). MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell, 97, 175-187.
2. ALLELY, M.C. & ALPS, B.J. (1988). The effects of the novel antianginal compound RS 43285 on myocardial conduction in the anaesthetized dog. Br. J. Pharmacol., 93, 375-382.
3. ALLELY, M.C. & ALPS, B.J. (1990). Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br. J. Pharmacol., 99, 5-6.
4. ALLEN, T.J. & CHAPMAN, R.A. (1996). Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br. J. Pharmacol., 118, 249-254.
5. BARHANIN, J., LESAGE, F., GUILLEMARE, E., FINK, M., LAZDUNSKI, M. & ROMEY, G. (1996). KvLQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature, 384, 78-80.
6. BILICZKI, P., VIRAG, L., IOST, N., PAPP, J.G. & VARRO, A. (2002). Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve. Br. J. Pharmacol., 137, 361-368.
7. BLACK, S.C., GRALINSKI, M.R., MCCORMACK, J.G., DRISCOLL, E.M. & LUCCHESI, B.R. (1994). Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion. J. Cardiovasc. Pharmacol., 24, 921-928.
8. CARMELIET, E. (1985). Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J. Pharmacol. Exp. Ther., 232, 817-825.
9. CHAITMAN, B.R., PEPINE, C.J., PARKER, J.O., SKOPAL, M.J., CHUMAKOVA, G., KUCH, J., WANG, W., SKETTINO, S.L. & WOLFF, A.A. (2004b). Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA, 21, 309-315.
10. CHAITMAN, B.R., SKETTINO, S.L., PARKER, J.O., HANLEY, P., MELUZIN, J., KUCH, J., PEPINE, C.J., WANG, W., NELSON, J.J., HEBERT, D.A., WOLFF, A.A. & for the MARISA Investigators (2004a). Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol., 43, 1375-1382.
11. CHANDLER, M.P., STANLEY, W.C., MORITA, H., SUZUKI, G., ROTH, B.A., BLACKBURN, B., WOLFF, A. & SABBAH, H.N. (2002). Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ. Res., 91, 278-280.
12. CLARKE, B., SPEDDING, M., PATMORE, L. & MCCORMACK, J.G. (1993). Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br. J. Pharmacol., 109, 748-750.
13. CLARKE, B., WYATT, K.M. & MCCORMACK, J.G. (1996). Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J. Mol. Cell. Cardiol., 28, 341-350.
14. COCCO, G., ROUSSEAU, M.F., BOUVY, T., CHERON, P., WILLIAMS, G., DETRY, J.M. & POULEUR, H. (1992). Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J. Cardiovasc. Pharmacol., 20, 131-138.
15. CONTI, C.R. (2003). Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina. Clin. Cardiol., 26, 161-162.
16. COURTEMANCHE, M., RAMIREZ, R.J. & NATTEL, S. (1998). Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am. J. Physiol., 275, H301-H321.
17. DERAKHCHAN, K., CARDINAL, R., BRUNET, S., KLUG, D., PHARAND, C., KUS, T. & SASYNIUK, B.I. (1998). Polymorphic ventricular tachycardias induced by D-sotalol and phenylephrine in canine preparations of atrioventricular block: initiation in the conduction system followed by spatially unstable re-entry. Cardiovasc. Res., 38, 617-630.
18. FENG, J., WANG, Z., LI, G.R. & NATTEL, S. (1997). Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. J. Pharmacol. Exp. Ther., 281, 384-392.
19. FERRARI, R., CICCHITELLI, G., MERLI, E., ANDREADOU, I. & GUARDIGLI, G. (2003). Metabolic modulation and optimization of energy consumption in heart failure. Med. Clin. North. Am., 87, 493-507.
20. GRALINSKI, M.R., BLACK, S.C., KILGORE, K.S., CHOU, A.Y., MCCORMACK, J.G. & LUCCHESI, B.R. (1994). Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc. Res., 28, 1231-1237.
21. JAIN, D., DASGUPTA, P., HUGHES, L.O., LAHIRI, A. & RAFTERY, E.B. (1990). Ranolazine (RS-43285) - a preliminary-study of a new antianginal agent with selective effect on ischemic myocardium. Eur. J. Clin. Pharmacol., 38, 111-114.
22. KEATING, M.T. & SANGUINETTI, M.C. (2001). Molecular and cellular mechanisms of cardiac arrhythmias. Cell, 104, 569-580.
23. LI, D., MELNYK, P., FENG, J., WANG, Z., PETRECCA, K., SHRIER, A. & NATTEL, S. (2000). Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation, 101, 2631-2638.
24. + current in human ventricular myocytes. Circ. Res., 78, 689-696.
25. Ca, contributes to rate-dependent changes of action potentials in human ventricular myocytes. Am. J. Physiol., 276, H98-H106.
26. LOUIS, A.A., MANOUSOS, I.R., COLETTA, A.P., CLARK, A.L. & CLELAND, J.G. (2002). Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact of nicorandil on angina. Combination assessment of ranolazine in stable angina. Enhancing recovery in coronary heart disease patients. Assessment of cardioversion using transoesophageal echocardiography. Azimilide post-infarct survival evaluation. Randomised evaluation of mechanical assistance for treatment of chronic heart failure. Eur. J. Heart Fail., 4, 111-116.
27. +, transient outward, and delayed rectifier currents in canine atrial myocytes. Circ. Res., 83, 158-166.
28. MCCORMACK, J.G., BARR, R.L., WOLFF, A.A. & LOPASCHUK, G.D. (1996). Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation, 93, 135-142.
29. MITCHESON, J.S., CHEN, J., LIN, M., CULBERSON, C. & SANGUINETTI, M.C. (2000). A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A., 97, 12329-12333.
30. NATTEL, S. & QUANTZ, M.A. (1988). Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc. Res., 22, 808-817.
31. NATTEL, S. & TALAJIC, M. (1988). Recent advances in understanding the pharmacology of amiodarone. Drugs., 36, 121-131.
32. PEPINE, C.J. & WOLFF, A.A. (1999). A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am. J. Cardiol., 84, 46-50.
33. RODEN, D.M., LAZZARA, R., ROSEN, M., SCHWARTZ, P.J., TOWBIN, J. & VINCENT, G.M. (1996). Multiple mechanisms in the long-QT syndrome: current knowledge, gaps, and future directions. Circulation, 94, 1996-2012.
34. SANGUINETTI, M.C. (1999). Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia. Ann. N.Y. Acad. Sci., 868, 406-413.
35. Ks potassium channel. Nature, 384, 80-83.
36. Kr potassium channel. Cell, 81, 299-307.
37. + current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol., 96, 195-215.
38. + current is composed of two currents in guinea pig atrial cells. Am. J. Physiol., 260, H393-H399.
39. THADANI, U., EZEKOWITZ, M., FENNEY, L. & CHIANG, Y.K. (1994). Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris Ranolazine Study Group. Circulation, 90, 726-734.
40. TRUDEAU, M.C., WARMKE, J.W., GANETZKY, B. & ROBERTSON, G.A. (1995). HERG, a human inward rectifier in the voltage-gated potassium channel family. Science, 269, 92-95.
41. WEERAPURA, M., NATTEL, S., CHARTIER, D., CABALLERO, R. & HEBERT, T.E. (2002). A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current Is MiRP1 the missing link? J. Physiol., 540, 15-27.
42. WOLFF, A.A. (2000). MARISA: Monotherapy assessment of ranolazine in stable angina. J. Am. Coll. Cardiol., 35, 408A (abstract).
43. WU, L., SHRYOCK, J.C., SONG, Y., LI, Y., ANTZELEVITCH, C. & BELARDINELLI, L. (2004). Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J. Pharmacol. Exp. Ther., (Epub ahead of print).
44. ZACHAROWSKI, K., BLACKBURN, B. & THIEMERMANN, C. (2001). Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur. J. Pharmacol., 418, 105-110.
45. ZHANG, S., ZHOU, Z., GONG, Q., MAKIELSKI, J.C. & JANUARY, C.T. (1999). Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ. Res., 84, 989-998.
46. ZYGMUNT, A.C., THOMAS, G.P., BELARDINELLI, L., BLACKBURN, B. & ANTZELEVITCH, C. (2002). Ranolazine produces ion channel effects similar to those observed with chronic amiodarone in canine ventricular myocytes. Pacing Clin. Electrophysiol., 24, 626 (abstract).